human inos

GW274150 is an orally active, selective and potent dual inhibitor of NADPH-dependent human nitric oxide synthase (iNOS) (Kd=40 nM) and rat inducible nitric oxide synthase (iNOS).GW274150 has a low activity against endothelial nitric oxide synthase (eNOS) and neuronal nitric oxide synthase (nNOS) in humans and rats. GW274150 showed protective effects in an inflammatory model of acute lung injury.

NOS-IN-1 (2-Imino-4-methylpiperidine acetate) is a potent and orally active inhibitor of NO synthase (NOS) isoforms. NOS-IN-1 exhibits IC50s of 0.1 μM, 0.2 μM, and 1.1μM for human iNOS (hiNOS), hnNOS and heNOS, respectively.

Glabridin (KB-289522) may serve as an anti-inflammatory agent in diabetes-related vascular dysfunction, through regulating the synthesis and activity of iNOS under high-glucose levels; may possess a therapeutic effect on metabolic disorders( such as diabetes and hyperglycemia), by modulating glucose metabolism through AMPK in skeletal muscle cells. Glabridin may have potential as a chemopreventive agent against liver Y metastasis, by inhibiting the invasion of human HCC cells.

L-NAME hydrochloride (L-NAME HCl), a cell-permeable NO synthase inhibitor, displays Ki values of 4.4 μM, 15 nM, and 39 nM, for iNOS (mouse) , nNOS (bovine) , and eNOS (human), respectively.

S-(2-aminoethyl) Isothiourea (dihydrobromide) is a non-selective inhibitor of all NOS isoforms. For human nNOS, eNOS, and iNOS, the Ki values are 1.8, 2.1, and 0.59 µM, respectively

Amentoflavone (3',8''-Biapigenin), as a potent inhibitor of CYP3A4 and CYP2C9, can interact with many other medications. CYP3A4 and CYP2C9 are proteins used for drug metabolism in the body. Amentoflavone also is an inhibitor of human cathepsin B. It has antimalarial activity in trials significant affinities towards the Delta-1, kappa opioid receptors (as an antagonist) and binds to benzodiazepine receptors. Amentoflavone may be a potential lead for a new type of anti-inflammatory agents having the dual inhibitory activity of group II phospholipase A2 and cyclooxygenase. Amentoflavone and quercetin differentially exerted suppression of PGE2 biosynthesis via downregulation of COX-2 iNOS expression.

1. Cornuside (Comuside) has immunomodulatory activity . 2. Cornuside suppresses expression levels of cytokine-induced proinflammatory and adhesion molecules in the human endothelial cells. 3. Cornuside can treat myocardial I R and protect the liver from CCl4-induced acute hepatotoxicity, by reducing oxidative stress and suppressing inflammatory responses. 4. Cornuside has anti-inflammatory activity by downregulations of iNOS and COX-2 due to NF-κB inhibition as well as the negative regulation of ERK1 2, p38, and JNK1 2 phosphorylations in RAW 264.7 cells. 5. Cornuside has protective potential against cerebral ischemic injury, may be due to the suppression of intracellular Ca(2+) elevation and caspase-3 activity, and improvements in mitochondrial energy metabolism and antioxidant properties.

Rosmanol has antioxidant activity, it can activate the antioxidant response element. Rosmanol has biphasic modulation of GABAA receptors, demonstrates CNS activity in mouse models of antinociception, antidepressant and anxiolysis. Rosmanol potently induce

GW274150 phosphate is a selective, orally active, and NADPH-dependent inhibitor of human inducible nitric oxide synthase (iNOS) (IC50: 2.19 μM; Kd: 40 nM) and rat iNOS (ED50: 1.15 μM).

L-NMMA acetate (Tilarginine acetate) is an inhibitor of nitric oxide synthase of all NOS isoforms (i.e. NOS1, NOS2, and NOS3). The Ki values are 0.18, 0.4, and 6 µM for nNOS, eNOS, and iNOS, respectively.

Compound AuL9, also known as iNOS TopoI-IN-1, is a multi-target hybrid molecule possessing anti-tumor, anti-inflammatory, and antioxidant properties. This compound effectively inhibits the growth of MCF-7 and MDA MB-231 breast cancer cells in vitro, exhibiting IC50 values of 3.5 μM and 6.3 μM respectively. It also prompts DNA damage and apoptosis in these cells by inhibiting human topoisomerase I (TopoI) with a K_i of 2.72 μM. Additionally, iNOS TopoI-IN-1 reduces the expression of iNOS by suppressing the activation of NF-kB, with a K_i of 1.49 μM.

COX-2-IN-48 (5-25) serves as an inhibitor of COX-2, exhibiting an IC50 of 51.7 nM against human COX-2. It displays anti-inflammatory and analgesic effects in various rodent models through inhibition of the NF-κB pathway. COX-2-IN-48 (5-25) inhibits the degradation of IκB, phosphorylation and nuclear translocation of NF-κB p65, and the expression of COX-2 and iNOS.

6-Formylpterin (Pterin-6-aldehyde) is an inhibitor of Xanthine Oxidase (Ki ~0.6 nM) with potent neuroprotective effects against transient IRI in gerbils.6-Formylpterin induces intracellular ROS generation in HL-60 cells as well as apoptosis ( 6-Formylpterin inhibits the expression of iNOS, produces hydrogen peroxide intracellularly and restores the impaired bactericidal activity of human neutrophils.

1. Ruscogenin has anti-inflammatory activity, suppressed zymosan A-evoked peritoneal total leukocyte migration in mice in a dose-dependent manner, 2. Ruscogenin inhibited adhesion of leukocytes to a human umbilical vein endothelial cell line (ECV34) injured by tumor necrosis factor-alpha (TNF-alpha) in a concentration-dependent manner. 3. Ruscogenin significantly attenuate LPS-induced acute lung injury via inhibiting expressions of TF and iNOS and NF-kappa B p65 activation.

GW274150 (dihydrochloride) is a potent and selective inhibitor of human and rat inducible nitric oxide synthase (iNOS), exhibiting oral activity and NADPH-dependence with an IC50 of 2.19 μM and Kd of 40 nM for human iNOS, and an ED50 of 1.15 μM for rat iNOS. It demonstrates reduced effectiveness against endothelial NOS (eNOS) and neuronal NOS (nNOS) in both species, and has shown protective effects in acute lung injury inflammation models [1] [2] [3].

23-epi-26-Deoxyactein (27-Deoxyactein) has anti-inflammatory activity, it inhibits nitric oxide production by reducing iNOS expression without affecting activity of the enzyme. It also has anti-cancer activity, it can inhibit growth of the MCF7 human breast cancer cells and induce cell cycle arrest at G1.

Xanthoxyletin shows potent antibacterial, fungicidal, and algicidal properties, it also has anticancer, and anti-inflammatory activities. It shows an inhibitory effect on iNOS protein expression at 10 microM, it also can inhibit the synthesis of nitric oxide and the protein expression of tumor necrosis factor-alpha and cyclooxygenase-2. Xanthoxyletin induces S phase arrest and apoptosis in human gastric adenocarcinoma SGC-7901 cells, the effects are associated with the DNA damage, apoptosis through mitochondrial dysfunction, and cell cycle arrest at S phase in a dose-dependent manner, it also can increase the production of reactive oxygen species.

SPSB2-iNOS inhibitory cyclic peptide-1, an inhibitor for the interaction between the SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, binds SPSB2 at the iNOS site with a K D of 4.4 nM. It is resistant to proteases pepsin, trypsin, and α-chymotrypsin and remains stable in human plasma and oxidative environments [1].